This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
UTMD Trades at a Premium to the Industry: How to Play the Stock?
by Debasmita Chatterjee
Utah Medical's Orion acquisition, strong cash reserves, improving margins and product expansion efforts support growth prospects and continued shareholder returns.
UTMDPositive Net Change EOLSPositive Net Change CGCNegative Net Change
medical
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
by Zacks Equity Research
Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
HALONegative Net Change JNJNegative Net Change MRKNegative Net Change ARGXNegative Net Change
biotechs medical pharmaceuticals
CVS Health Trades at a Discount to Industry: How to Play the Stock?
by Moumi Mondal
CVS trades below industry peers as Aetna margins recover, pharmacy trends improve and Health Services gains momentum, but 340B headwinds persist.
CVSNegative Net Change UNHNegative Net Change ELVNegative Net Change
medical medical-devices
Is it the Right Time to Add Phibro Stock to Your Portfolio?
by Zacks Equity Research
PAHC's Animal Health gains from MFA, vaccine and mineral nutrition growth, but tariffs, costs and currency swings remain key risks to its outlook.
PAHCNegative Net Change ABTNegative Net Change GMEDNegative Net Change VCYTPositive Net Change
medical medical-devices
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
by Zacks Equity Research
SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.
SNNPositive Net Change WSTNegative Net Change GMEDNegative Net Change VCYTPositive Net Change
medical medical-devices
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now
by Zacks Equity Research
HIMS' top line is driven by demand for weight loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
HIMSNegative Net Change MMSIPositive Net Change GMEDNegative Net Change OMNegative Net Change
medical medical-devices
Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
by Zacks Equity Research
TDOC expands Solo with AI tools that streamline virtual assessments and clinical documentation, targeting simpler workflows for hospitals.
TDOCNegative Net Change PAHCNegative Net Change WGSNegative Net Change CONPositive Net Change
artificial-intelligence medical smart-health
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
by Zacks Equity Research
BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.
BAYRYNegative Net Change REGNNegative Net Change JNJNegative Net Change
biotechs medical pharmaceuticals
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
by Zacks Equity Research
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
NVSNegative Net Change PFENegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
UnitedHealth Gears Up for Q3 Earnings: Should Investors Buy the Stock?
by Kaibalya Pravo Dey
UNH's Q3 earnings are expected to jump 41.1% despite revenue headwinds. Can improving cost management and restructuring drive further stock gains?
UNHNegative Net Change HUMNegative Net Change MOHPositive Net Change
earnings-preview healthcare hmo insurance medical